Tags

Type your tag names separated by a space and hit enter

Miltefosine and cutaneous leishmaniasis.
Curr Opin Infect Dis. 2012 Apr; 25(2):141-4.CO

Abstract

PURPOSE OF REVIEW

Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed.

RECENT FINDINGS

Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran. Severe cutaneous leishmaniasis forms successfully treated with miltefosine are reported.

SUMMARY

The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large-scale use in the inner regions of the endemic countries. Miltefosine also shows activity in severe or refractory cases. However, this review points out the need for further investment on clinical research into cutaneous leishmaniasis treatment.

Authors+Show Affiliations

Serviço de Imunologia, Complexo Hospitalar Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia. prlmachado@hotmail.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22248979

Citation

Machado, Paulo R L., and Gerson Penna. "Miltefosine and Cutaneous Leishmaniasis." Current Opinion in Infectious Diseases, vol. 25, no. 2, 2012, pp. 141-4.
Machado PR, Penna G. Miltefosine and cutaneous leishmaniasis. Curr Opin Infect Dis. 2012;25(2):141-4.
Machado, P. R., & Penna, G. (2012). Miltefosine and cutaneous leishmaniasis. Current Opinion in Infectious Diseases, 25(2), 141-4. https://doi.org/10.1097/QCO.0b013e3283509cac
Machado PR, Penna G. Miltefosine and Cutaneous Leishmaniasis. Curr Opin Infect Dis. 2012;25(2):141-4. PubMed PMID: 22248979.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine and cutaneous leishmaniasis. AU - Machado,Paulo R L, AU - Penna,Gerson, PY - 2012/1/18/entrez PY - 2012/1/18/pubmed PY - 2012/4/26/medline SP - 141 EP - 4 JF - Current opinion in infectious diseases JO - Curr Opin Infect Dis VL - 25 IS - 2 N2 - PURPOSE OF REVIEW: Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed. RECENT FINDINGS: Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran. Severe cutaneous leishmaniasis forms successfully treated with miltefosine are reported. SUMMARY: The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large-scale use in the inner regions of the endemic countries. Miltefosine also shows activity in severe or refractory cases. However, this review points out the need for further investment on clinical research into cutaneous leishmaniasis treatment. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/22248979/Miltefosine_and_cutaneous_leishmaniasis_ L2 - https://doi.org/10.1097/QCO.0b013e3283509cac DB - PRIME DP - Unbound Medicine ER -